Brokers Offer Predictions for OFIX Q2 Earnings

ORTHOFIX MEDICAL INC. (NASDAQ:OFIX - Free Report) - Barrington Research issued their Q2 2025 EPS estimates for ORTHOFIX MEDICAL in a research report issued on Monday, June 23rd. Barrington Research analyst M. Petusky anticipates that the medical device company will earn ($0.72) per share for the quarter. Barrington Research currently has a "Strong-Buy" rating and a $16.00 target price on the stock. The consensus estimate for ORTHOFIX MEDICAL's current full-year earnings is ($2.81) per share. Barrington Research also issued estimates for ORTHOFIX MEDICAL's Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($2.34) EPS and FY2027 earnings at ($1.64) EPS.

Several other equities analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of ORTHOFIX MEDICAL from a "hold" rating to a "sell" rating in a report on Friday. JMP Securities reiterated a "market perform" rating on shares of ORTHOFIX MEDICAL in a report on Friday, June 6th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.50.

ORTHOFIX MEDICAL Stock Performance

NASDAQ:OFIX traded up $0.05 during midday trading on Thursday, hitting $11.09. The company's stock had a trading volume of 999,465 shares, compared to its average volume of 286,889. ORTHOFIX MEDICAL has a fifty-two week low of $10.24 and a fifty-two week high of $20.73. The firm's 50 day moving average is $11.85 and its 200-day moving average is $15.20. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.71 and a quick ratio of 1.50. The firm has a market cap of $434.51 million, a P/E ratio of -3.01 and a beta of 0.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lazard Asset Management LLC purchased a new position in shares of ORTHOFIX MEDICAL during the 4th quarter valued at approximately $45,000. US Bancorp DE lifted its position in shares of ORTHOFIX MEDICAL by 684.6% during the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after buying an additional 4,950 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of ORTHOFIX MEDICAL during the 4th quarter valued at approximately $112,000. Tower Research Capital LLC TRC lifted its position in shares of ORTHOFIX MEDICAL by 120.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock valued at $148,000 after buying an additional 4,627 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of ORTHOFIX MEDICAL during the 1st quarter valued at approximately $150,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Insiders Place Their Bets

In other news, insider Aviva Mcpherron sold 3,728 shares of the stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the transaction, the insider now owns 46,322 shares in the company, valued at $486,844.22. This trade represents a 7.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Engine Capital Management, Lp bought 100,000 shares of the firm's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $12.31 per share, for a total transaction of $1,231,000.00. Following the transaction, the insider now directly owns 3,544,807 shares in the company, valued at approximately $43,636,574.17. This represents a 2.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 112,250 shares of company stock worth $1,380,970 and have sold 7,620 shares worth $91,168. Insiders own 1.30% of the company's stock.

ORTHOFIX MEDICAL Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.